281 related articles for article (PubMed ID: 9550503)
1. Profiling risk and new therapeutic interventions: looking ahead.
Shepherd J
Am J Med; 1998 Feb; 104(2A):19S-22S. PubMed ID: 9550503
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
Hunninghake DB
Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
[TBL] [Abstract][Full Text] [Related]
3. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
4. Achieving LDL-C target levels: the role of statins.
Lablanche JM
Curr Med Res Opin; 2001; 16(4):285-95. PubMed ID: 11268713
[TBL] [Abstract][Full Text] [Related]
5. Managing dyslipidemia in the high-risk patient.
Stein EA
Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
[TBL] [Abstract][Full Text] [Related]
6. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
7. [Statins in primary prevention of coronary heart disease].
Paulweber B
Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
9. Novel approaches to lipid lowering: what is on the horizon?
Brown WV
Am J Cardiol; 2001 Mar; 87(5A):23B-27B. PubMed ID: 11256846
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials.
Eisenberg DA
Am J Med; 1998 Feb; 104(2A):2S-5S. PubMed ID: 9550499
[TBL] [Abstract][Full Text] [Related]
13. Low-density lipoproteins and risk for coronary artery disease.
Ballantyne CM
Am J Cardiol; 1998 Nov; 82(9A):3Q-12Q. PubMed ID: 9819098
[TBL] [Abstract][Full Text] [Related]
14. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
Rader DJ; Davidson MH; Caplan RJ; Pears JS
Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
[TBL] [Abstract][Full Text] [Related]
15. Treating hypercholesterolemia: looking forward.
Gotto AM
Clin Cardiol; 2003 Jan; 26(1 Suppl 1):I21-8. PubMed ID: 12539819
[TBL] [Abstract][Full Text] [Related]
16. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
[TBL] [Abstract][Full Text] [Related]
17. [Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients].
Tachibana E; Watanabe I; Nagao K; Kanmatsuse K
J Cardiol; 2000 Apr; 35(4):277-85. PubMed ID: 10791271
[TBL] [Abstract][Full Text] [Related]
18. Identifying patients for aggressive cholesterol lowering: the risk curve concept.
Robinson JG; Stone NJ
Am J Cardiol; 2006 Nov; 98(10):1405-8. PubMed ID: 17134640
[TBL] [Abstract][Full Text] [Related]
19. 2017 Taiwan lipid guidelines for high risk patients.
Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups.
Blasetto JW; Stein EA; Brown WV; Chitra R; Raza A
Am J Cardiol; 2003 Mar; 91(5A):3C-10C; discussion 10C. PubMed ID: 12646336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
